- Details
- Zach Klaassen hosts Mark Tyson for a discussion on the noninvasive urinary genomic biomarker test, Cxbladder. Dr. Tyson explains that Cxbladder Detect assesses bladder cancer risk in patients with microscopic hematuria by analyzing urine for specific mRNA biomarkers. The test aims to reduce invasive diagnostics like cystoscopy, aligning with AUA guidelines for a risk-stratified approach. Their dec...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...
|
- Details
- Sam Chang and Sia Daneshmand explore the impact of Cysview blue light cystoscopy on cancer recurrence. Dr. Daneshmand presents a comprehensive registry study from USC which shows significantly lower recurrence rates in patients examined with blue light cystoscopy, when compared to a white light patient group. Notwithstanding potential variables like modern management techniques, they attribute thi...
|
- Details
- Siamak Daneshmand shares insights Phase 2 Study of the "Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2". For patients that present with NMIBC who have carcinoma in situ (CIS), there is a high risk of disease progression. In more advanced bladder cancer FGFR inhibition has dem...
|
- Details
- Ashish Kamat hosts Colin Dinney in a discussion on Adstiladrin Gene Therapy for BCG Unresponsive Disease, highlighting an unmet need for effective second-line therapies for patients suffering from non-muscle invasive bladder cancer. He reveals that the Adstiladrin Phase 3 trial showed promising results, with a complete response rate of 53% for carcinoma in situ (CIS) at three months. Citing its co...
|
- Details
- Sam Chang speaks with Tara Cumming and Meredith Donahue who share their insights on implementing an efficient system for administering instillation therapy for bladder cancer patients at Vanderbilt. Cumming and Donahue were instrumental in designing this streamlined process, which they call the BCG Clinic, where patients receive treatment one day each week, improving not just patient care but also...
|
- Details
- In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58 months,...
|
- Details
- In this conversation, moderated by Ashish Kamat, Paulo Gontero and Gary Steinberg, discuss the treatment and management of intermediate risk, non-muscle invasive bladder cancer (NMIBC). Gontero explains their use of the 2021 EAU guidelines to determine a patient's risk category based on several variables. He emphasizes the complexity of the intermediate risk category and the further need to sub-st...
|
- Details
- In a discussion, Ashish Kamat and Girish Kulkarni delve into the Theralase ® project of intravesical photodynamic therapy for non-muscle invasive bladder cancer. This study, led by Dr. Kulkarni, employs photo-dynamic therapy in a phase two trial for BCG unresponsive bladder cancer, with promising early results. The procedure uses a ruthenium-based photosensitizer and a laser light that creates oxy...
|
- Details
- In this conversation, Siamak Daneshmand joins Sam Chang in discussing a new treatment option for bladder cancer called TAR-200. TAR-200 is a pretzel-shaped device that delivers gemcitabine, a chemotherapy drug, directly into the bladder over a specified period of time. The conversation focuses on the late-breaking abstract of the SunRISe-1 trial, which evaluates the efficacy of TAR-200 in BCG unre...
|
